Pierre Bories, Mojca Jongen-Lavrencic, Laimonas Griškevičius, Thomas Pabst, David de Leeuw, Gerwin A. Huls, Nicolas Boissel, Arnaud Pigneux, Steffen Boettcher, Mariola Dymkowska, Christiane Andrieu, Elena Fernandez, Paul Baverel, Vaia Stavropoulou, Michael Sanderson, Vladimir Kirkin, Philippe Legenne, Marion Subklewe. "Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication." Blood, 2025. doi:10.1182/blood-2025-3419